Key result
Acute right cymba aLL-tVNS reduced burst frequency from baseline (Coef. -4.8, p<0.001) but did not significantly differ from active control for MSNA or HRV variables.
Why the study?
Auricular low-level transcutaneous vagus nerve stimulation (aLL-tVNS) has emerged as a promising technology for cardiac arrhythmia management but remains experimental, with its hypothesized modulation of autonomic balance through sympathetic reduction and increased heart rate variability requiring investigation.
Does auricular low-level transcutaneous vagus nerve stimulation reduce sympathetic tone and increase heart rate variability in healthy men compared to active control stimulation?
RCT (n=28)
Double-blind
Crossover
Does auricular low-level transcutaneous vagus nerve stimulation reduce sympathetic tone and increase heart rate variability in healthy men compared to active control stimulation?
Acute auricular transcutaneous vagus nerve stimulation does not significantly alter sympathetic tone or heart rate variability compared to active control in healthy men.
No benefit of acute aLL-tVNS over control for MSNA or HRV in healthy men; challenges prior non-RCT suggestions of vagal modulation.
Introduction: Auricular low-level transcutaneous vagus nerve stimulation (aLL-tVNS) has emerged as a promising technology for cardiac arrhythmia management but is still experimental. In this physiological study, we hypothesized that aLL-tVNS modulated the autonomic nervous balance through a reduction of sympathetic tone and an increase in heart rate variability (HRV). We investigated the muscle sympathetic nerve activity (MSNA) recorded by microneurography during vagally mediated aLL-tVNS and active control on healthy volunteers. Methods: In this crossover, double-blind controlled study, healthy men ( N = 28; 27 ± 4 years old) were assigned to aLL-tVNS applied to cymba and lobe (active control) of the right ear. Each participant was randomly allocated to the three sequences (5 Hz, 20 Hz, and active control-5 Hz) during one session. MSNA signal was recorded at rest, during voluntarily apnea and aLL-tVNS. Sympathetic activity was expressed as: 1) number of bursts per minute (burst frequency, BF) and 2) MSNA activity calculated as BF x mean burst amplitude and expressed as changes from baseline (%). RR intervals, HRV parameters and sympathetic activity were analyzed during 5 min-baseline, 10 min-stimulation, and 10 min-recovery periods. Mixed regression models were performed to evaluate cymba-(5—20 Hz) effects on the parameters with stimulation. Results: During apnea and compared to baseline, BF and MSNA activity increased ( p = 0.002, p = 0.001, respectively). No stimulation effect on RR intervals and HRV parameters were showed excepted a slightly increase of the LF/HF ratio with stimulation in the cymba-5Hz sequence (coef. ± SE: 0.76 ± 0.32%; p = 0.02). During stimulation, reductions from baseline in BF (Coef. ± SE: −4.8 ± 1.1, p < 0.001) was observed but was not statistically different from that one in the active control. Reduction of MSNA activity was not significantly different between sequences. Conclusion: Acute right cymba aLL-tVNS did not induce any overall effects neither on heart rate, HRV nor MSNA variables on healthy subjects when compared to active control. Interestingly, these findings questioned the role of active controls in medical device clinical trials that implied subjective endpoints.
No takes yet. Share an insight, caveat, or question.
Gauthey et al. (2020) conducted an RCT in Healthy subjects (n=28). Auricular low-level transcutaneous vagus nerve stimulation (aLL-tVNS) vs. Active control (lobe stimulation) was evaluated on Muscle sympathetic nerve activity (MSNA) and heart rate variability (HRV). Acute right cymba aLL-tVNS reduced burst frequency from baseline (Coef. -4.8, p<0.001) but did not significantly differ from active control for MSNA or HRV variables.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: